23,566 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC bought a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,566 shares of the company’s stock, valued at approximately $1,728,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. CWM LLC increased its holdings in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the last quarter. Comerica Bank lifted its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Osaic Holdings Inc. boosted its position in Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Mirum Pharmaceuticals by 14.9% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock valued at $97,000 after purchasing an additional 248 shares during the last quarter. Finally, Longboard Asset Management LP acquired a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $214,000.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MIRM. TD Cowen upgraded shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, September 25th. Citizens Jmp lifted their target price on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a report on Friday, December 19th. HC Wainwright reissued a “buy” rating and set a $102.00 target price (up previously from $81.00) on shares of Mirum Pharmaceuticals in a research report on Tuesday. Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Finally, JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $102.00.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock opened at $91.05 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The company has a market cap of $4.68 billion, a PE ratio of -105.87 and a beta of 0.48. The firm has a fifty day moving average price of $75.05 and a two-hundred day moving average price of $69.27. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $93.70.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. During the same quarter in the prior year, the business earned ($0.30) earnings per share. The firm’s revenue for the quarter was up 47.1% on a year-over-year basis. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.